⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 19, 2024Journal of Allergy and Clinical Immunology GlobalOpen Access

Predicting responses to omalizumab in antihistamine-refractory chronic urticaria: A real-world longitudinal study

Hyun Young Lee Hyun-Seob Jeon Jae-Hyuk Jang Young‐Soo Lee Yoo Seob Shin Dong‐Ho Nahm Hae‐Sim Park Young‐Min Ye

View Full Paper

Ask AI

Bookmark

Share

Abstract

Treating chronic urticaria (CU) that is unresponsive to H1-antihistamines (H1AHs) is challenging, and the real-world effectiveness of omalizumab remains unclear.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lee et al. (2024) studied this question.

synapsesocial.com/papers/68e73502b6db6435876aeb17 https://doi.org/10.1016/j.jacig.2024.100245

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Omalizumab in Chronic Spontaneous Urticaria: A Real-World Study on Effectiveness, Safety and Predictors of Treatment Outcome2024 · 18 citations
2Treatment Approaches for Omalizumab-Refractory Chronic Spontaneous UrticariaNarrative Review · 2026
3Low Total IgE Predicts Non-Response to Omalizumab in Chronic Spontaneous Urticaria: A 10-Year Real-Life Study2025 · 1 citations
4A Retrospective Study of Outcome in Omalizumab Therapy in Chronic Urticaria, a Real Experience on 36 Kuwaiti Patients from a Single Tertiary Dermatology Center2024
5Efficacy of Standard‐Dose Omalizumab Against Chronic Urticaria: A Real‐World StudyCohort Study · 2025